ASCO Rapid Recommendation | Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer. 19 Sep, 2022 | 12:31h | UTC Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation – Journal of Clinical Oncology
Open access
Open access